Successsful Voriconazole Treatment of Disseminated Fusarium Infection in an Immunocompromised Patient | Zendy

S. Consigny | Zendy; Nathalie Dhédin | Zendy; A. Datry | Zendy; Sylvain Choquet | Zendy; Véronique Leblond | Zendy; O. Chosidow | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Successsful Voriconazole Treatment of Disseminated Fusarium Infection in an Immunocompromised Patient

Author(s) -

S. Consigny,

Nathalie Dhédin,

A. Datry,

Sylvain Choquet,

Véronique Leblond,

O. Chosidow

Publication year - 2003

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/375842

Subject(s) - voriconazole , fusariosis , medicine , neutropenia , amphotericin b , fusarium , refractory (planetary science) , chemotherapy , dermatology , antifungal , biology , horticulture , astrobiology

Fusarium infection is known to cause major morbidity and mortality in immunocompromised hosts. We report the successful treatment of disseminated Fusarium infection with skin manifestations in a severely neutropenic, immunocompromised host with voriconazole, a new second-generation triazole. Voriconazole might be an alternative therapy for patients with neutropenia who have fusariosis that is refractory or unresponsive to amphotericin B or its liposomal formulation.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research